Hyaluronic Acid Derivatives for Translational Medicines

Kim, Hyemin; Shin, Myeonghwan; Han, Seulgi; Kwon, Woosung; Hahn, Sei Kwang

doi:10.1021/acs.biomac.9b00564

Cited by 72 publications

(58 citation statements)

References 123 publications

(239 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shortly after tissue injury with vascular denudation, there is an increase in the HA content of the wound, following which, it binds to the fibrin clot and reorganizes the clot into an HA-fibrin matrix ( 22 ). From the synthesis perspective, HA provides an excellent building block because of the presence of multiple functional groups on its backbone ( 23 ). On the basis of this rationale, CBP and VBP were conjugated to HA using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)/sulfo-NHS ( N -hydroxysuccinimide)–mediated coupling reactions ( Fig.…”

Section: Resultsmentioning

confidence: 99%

“…HA is also a key molecule in the regulation of many cellular and biological processes, and in particular, it is the primary macromolecular regulator for wound healing following vascular injury (22). Given its specific biological and bioactive properties, HA-based therapeutic formulations have been approved and used clinically for the treatment of arthritis and skin diseases (23). The degree of modification of HA is within 15%, less than the thresholds for affecting biological functions such as the interaction with CD44 receptors (36).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A polymer-based systemic hemostatic agent

et al. 2020

View full text Add to dashboard Cite

Uncontrolled noncompressible hemorrhage is a major cause of mortality following traumatic injuries in civilian and military populations. An injectable hemostat for point-of-care treatment of noncompressible hemorrhage represents an urgent medical need. Here, we describe an injectable hemostatic agent via polymer peptide interfusion (HAPPI), a hyaluronic acid conjugate with a collagen-binding peptide and a von Willebrand factor–binding peptide. HAPPI exhibited selective binding to activated platelets and promoted their accumulation at the wound site in vitro. In vivo studies in mouse tail vein laceration model demonstrated a reduction of >97% in both bleeding time and blood loss. A 284% improvement in the survival time was observed in the rat inferior vena cava traumatic model. Lyophilized HAPPI could be stably stored at room temperature for several months and reconstituted during therapeutic intervention. HAPPI provides a potentially clinically translatable intravenous hemostat.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A polymer-based systemic hemostatic agent

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Even though much effort has been devoted to biomedical applications of HA-NPs, only a few NPs are at the clinical stage. Several limiting issues need to be addressed to minimize the gap between basic research and its clinical translations [ 126 ]. The production, synthetic modification, and precise characterization of HA and HA-NPs should be accurately performed in accordance with the clinical requirements.…”

Section: Discussionmentioning

confidence: 99%

Hyaluronic Acid Nanoparticles as Nanomedicine for Treatment of Inflammatory Diseases

Rao

Rho

et al. 2020

Pharmaceutics

View full text Add to dashboard Cite

Owing to their unique biological functions, hyaluronic acid (HA) and its derivatives have been explored extensively for biomedical applications such as tissue engineering, drug delivery, and molecular imaging. In particular, self-assembled HA nanoparticles (HA-NPs) have been used widely as target-specific and long-acting nanocarriers for the delivery of a wide range of therapeutic or diagnostic agents. Recently, it has been demonstrated that empty HA-NPs without bearing any therapeutic agent can be used therapeutically for the treatment of inflammatory diseases via modulating inflammatory responses. In this review, we aim to provide an overview of the significant achievements in this field and highlight the potential of HA-NPs for the treatment of inflammatory diseases.

show abstract

“…Furthermore, HA is widely used since its long polysaccharide chain possesses multiple functional groups, namely carboxylic acid, hydroxyl groups and the N-acetyl group, that allow covalent modifications and, therefore, the design of tailor-made biomedical products [182,188]. Consequently, HA is used for multiple biomedical applications, including regenerative medicine, tissue engineering, drug delivery, cell therapy, and three-dimensional (3D) cell culture [178,[189][190][191][192][193][194].…”

Section: Hyaluronic Acidmentioning

confidence: 99%

Aptamer-Functionalized Natural Protein-Based Polymers as Innovative Biomaterials

et al. 2020

View full text Add to dashboard Cite

Biomaterials science is one of the most rapidly evolving fields in biomedicine. However, although novel biomaterials have achieved well-defined goals, such as the production of devices with improved biocompatibility and mechanical properties, their development could be more ambitious. Indeed, the integration of active targeting strategies has been shown to allow spatiotemporal control of cell–material interactions, thus leading to more specific and better-performing devices. This manuscript reviews recent advances that have led to enhanced biomaterials resulting from the use of natural structural macromolecules. In this regard, several structural macromolecules have been adapted or modified using biohybrid approaches for use in both regenerative medicine and therapeutic delivery. The integration of structural and functional features and aptamer targeting, although still incipient, has already shown its ability and wide-reaching potential. In this review, we discuss aptamer-functionalized hybrid protein-based or polymeric biomaterials derived from structural macromolecules, with a focus on bioresponsive/bioactive systems.

show abstract

Hyaluronic Acid Derivatives for Translational Medicines

Cited by 72 publications

References 123 publications

A polymer-based systemic hemostatic agent

A polymer-based systemic hemostatic agent

Hyaluronic Acid Nanoparticles as Nanomedicine for Treatment of Inflammatory Diseases

Aptamer-Functionalized Natural Protein-Based Polymers as Innovative Biomaterials

Contact Info

Product

Resources

About